William Cookson is Professor of Genomic Medicine at Imperial College London and Head of Respiratory Sciences for the College. He is Head of the Asmarley Centre for Genomic Medicine at the National Heart and Lung Institute. He won a Joint Wellcome Senior Investigator Award with Professor Miriam Moffatt in 2011, and was elected to the College of NIHR Senior Investigators in 2013.
Professor Cookson initially trained as a respiratory physician, before receiving a D.Phil. in human genetics at Oxford in 1994. He was a Professor of Human Genetics at the University of Oxford between 1998 and 2004. Over the past twenty-five years he and Miriam Moffatt have developed a successful research group devoted to understanding the genetic causes of asthma (Zhang Y. et al., Nature Genetics 2003; Allen M. et al., Nature Genetics 2003; Moffatt M. et al., Nature 2007; Moffatt M. et al., New England Journal of Medicine 2010).
Many of the genes identified by these studies are concentrated in the airway epithelium, so that asthma is now recognised as a disease of the airway mucosa. Genes identified by the group such as ORMDL3, IL33, TSLP and IL18R1 are the focus for new asthma therapies.
In addition to detailed investigation of the functions of these major asthma genes, the group are also systematically charting inflammatory pathways by gene expression, RNA sequencing, and gene knockdowns in cellular models of inflammation. These studies are the basis for developing new therapies for asthma and mucosal inflammation (genomic pharmacology).
The group have pioneered gene expression mapping to identify the function of loci identified by genome-wide association studies. The resulting comprehensive maps of expression quantitative trait loci (eQTLs) (Dixon A. et al., Nature Genetics 2007, Liang L. et al, Genome Resarch 2013) have aided the systematic detection of genes underlying many complex disorders and have contributed to the 1000 genomes project.
The group are currently concentrating their mapping efforts on the epigenome, by measuring changes in the methylation of particular regions of the genome that regulate gene expression. Their early results suggest that this will be a rich source of new biological insights into asthma and allergic diseases.
A parallel strand in the group's work has been to understand at the molecular level the interactions between genes and environment, with the realistic hope that this will lead to effective prevention of the disease (Cookson, Nature 1999). Cookson was co-coordinator of the mutinational GABRIEL consortium that made many discoveries about the effects of genes and environment on asthma in Europe (Moffatt M. et al., New England Journal of Medicine 2010; Ege M. et al., New England Journal of Medicine 2011).
In the face of a prevailing wisdom that the airways of normal individuals are completely sterile, the group were first to use DNA sequencing to show that the airways contain a characteristic microbiota, and that this bacterial community is disturbed in patients with asthma and COPD (Hilty et al., PLoSOne 2010). Studies of the airway microbiome are now a central part of the group's research, as they apply culture-independent sequencing methods to other lung diseases, including pulmonary fibrosis, cystic fibrosis and bronchiectasis.
The group are developing large-scale genomic studies of lung cancer, in collaboration with G.M. Lathrop at McGill Genome Centre in Canada. They are currently sequencing multiple lung cancers to identify the full spectrum of mutations driving the disease. At the same time the group are measuring global gene expression to define new therapeutic targets.
et al., 2022, Evidence of immunometabolic dysregulation and airway dysbiosis in athletes susceptible to respiratory illness, Ebiomedicine, Vol:79, ISSN:2352-3964, Pages:1-16
et al., 2022, <i>Mycobacterium avium</i> complex (MAC) genomics and transmission in a London hospital
et al., 2022, Integrated genomics point to immune vulnerabilities in pleural mesothelioma (vol 11, 19138, 2021), Scientific Reports, Vol:12, ISSN:2045-2322
et al., 2022, Airway mucins promote immunopathology in virus-exacerbated chronic obstructive pulmonary disease., Journal of Clinical Investigation, Vol:132, ISSN:0021-9738, Pages:1-16
et al., 2022, A pandemic lesson for global lung diseases: exacerbations are preventable., American Journal of Respiratory and Critical Care Medicine, Vol:205, ISSN:1073-449X, Pages:1271-1280